Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hubert H Fernandez

Showing results (41-50 of 260) with videos related to

Pageof 26
Sort By:
Parkinsonism & Related Disorders|November 23, 2024
Dosing dilemma: Can reduced botulinum neurotoxin type-A doses offer longer-lasting effects in cervical dystonia?Avery Kundrick, Claire Sonneborn, Hubert H Fernandez
Cleveland Clinic Journal of Medicine|February 4, 2012
Deep brain stimulation: what can patients expect from it?Andre Machado, Hubert H Fernandez, Milind Deogaonkar
Parkinsonism & Related Disorders|August 29, 2024
Patellofemoral instability as a differential for bizarre functional gaitEkhlas Assaedi, Leila Saadatpour, Hubert H Fernandez
Parkinsonism & Related Disorders|October 18, 2011
What's the "catch" in upper-limb post-stroke spasticity: expanding the role of botulinum toxin applicationsRaymond L Rosales, Petr Kanovsky, Hubert H Fernandez
Parkinsonism & Related Disorders|February 8, 2023
Early-onset parkinsonism and hereditary spastic paraplegia type 7: pearls and pitfallsOliver Phillips, Alexa M Amato, Hubert H Fernandez
Expert Opinion on Pharmacotherapy|October 3, 2003
Rationale for current therapies in Parkinson's diseaseJanet Romrell, Hubert H Fernandez, Michael S Okun
Expert Review of Neurotherapeutics|June 15, 2007
Role of deep brain stimulation targeted to the pedunculopontine nucleus in Parkinson's diseaseChristopher Kenney, Hubert H Fernandez, Michael S Okun
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|February 1, 2003
Unrecognized parkinsonism in acute care medical patients receiving neurological consultationsJoseph H Friedman, Rachel Skeete, Hubert H Fernandez
Parkinsonism & Related Disorders|June 25, 2018
Predicting early cognitive decline in newly-diagnosed Parkinson's patients: A practical modelOlivia Hogue, Hubert H Fernandez, Darlene P Floden
Drug Safety|June 20, 2003
Treatment of psychosis in Parkinson's disease: safety considerationsHubert H Fernandez, Martha E Trieschmann, Joseph H Friedman
Pageof 26

Showing results (41-50 of 260) with videos related to

Sort By:
Pageof 26
Parkinsonism & Related Disorders|November 23, 2024
Dosing dilemma: Can reduced botulinum neurotoxin type-A doses offer longer-lasting effects in cervical dystonia?Avery Kundrick, Claire Sonneborn, Hubert H Fernandez
Cleveland Clinic Journal of Medicine|February 4, 2012
Deep brain stimulation: what can patients expect from it?Andre Machado, Hubert H Fernandez, Milind Deogaonkar
Parkinsonism & Related Disorders|August 29, 2024
Patellofemoral instability as a differential for bizarre functional gaitEkhlas Assaedi, Leila Saadatpour, Hubert H Fernandez
Parkinsonism & Related Disorders|October 18, 2011
What's the "catch" in upper-limb post-stroke spasticity: expanding the role of botulinum toxin applicationsRaymond L Rosales, Petr Kanovsky, Hubert H Fernandez
Parkinsonism & Related Disorders|February 8, 2023
Early-onset parkinsonism and hereditary spastic paraplegia type 7: pearls and pitfallsOliver Phillips, Alexa M Amato, Hubert H Fernandez
Expert Opinion on Pharmacotherapy|October 3, 2003
Rationale for current therapies in Parkinson's diseaseJanet Romrell, Hubert H Fernandez, Michael S Okun
Expert Review of Neurotherapeutics|June 15, 2007
Role of deep brain stimulation targeted to the pedunculopontine nucleus in Parkinson's diseaseChristopher Kenney, Hubert H Fernandez, Michael S Okun
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|February 1, 2003
Unrecognized parkinsonism in acute care medical patients receiving neurological consultationsJoseph H Friedman, Rachel Skeete, Hubert H Fernandez
Parkinsonism & Related Disorders|June 25, 2018
Predicting early cognitive decline in newly-diagnosed Parkinson's patients: A practical modelOlivia Hogue, Hubert H Fernandez, Darlene P Floden
Drug Safety|June 20, 2003
Treatment of psychosis in Parkinson's disease: safety considerationsHubert H Fernandez, Martha E Trieschmann, Joseph H Friedman
Pageof 26